Key Insights

Highlights

Treatment Research

8 treatments under study, led by Dose Level 2b 6 X 107 Cellsm2

Related Conditions

Often studied with 8 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

50.0%

1 terminated out of 2 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

2Total
Phase 1 (1)
Phase 2 (1)

Trial Status

Terminated1
Recruiting1

Clinical Trials (2)

Showing 2 of 2 trials
NCT04664179Phase 1RecruitingPrimary

EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma

NCT05011058Phase 2Terminated

An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas

Showing all 2 trials

Research Network

Common Treatments

  • Dose Level 2b 6 X 107 Cellsm21
  • Dose Level 2a 6 X 107 Cellsm21
  • Dose Level 3a 2 X 108 Cellsm21
  • Nanatinostat1
  • Dose Level 1b 2 X 107 Cellsm21

Active Sponsors

  • Baylor College of Medicine1
  • Viracta Therapeutics, Inc.1
  • The Methodist Hospital Research Institute1
  • National Cancer Institute (NCI)1

Top Investigators

Related Conditions

  • Ebvrelated Lymphoproliferative Disorder2
  • Ebvpositive Dlbcl Nos1
  • Ebvrelated Ptld1
  • Epsteinbarr Viruspositive Ebv Relapsedrefractory Lymphomas1
  • Epsteinbarr Virus Associated Lymphoma1

Activity Timeline